Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

NCT03680521 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG: Sitravatinib
DRUG: Nivolumab

Sponsor

Mirati Therapeutics Inc.